

THE ROLE OF MICROTUBULES IN CELL BIOLOGY,
NEUROBIOLOGY, AND ONCOLOGY

CANCER DRUG DISCOVERY AND DEVELOPMENT

BEVERLY A. TEICHER, PhD
SERIES EDITOR

The Role of Microtubules in Cell Biology, Neurobiology, and Oncology, edited by Tito Fojo, 2008

Checkpoint Responses in Cancer Therapy, edited by Wei Dai, 2008

Cancer Proteomics: From Bench to Bedside, edited by Sayed S. Daoud, 2008

Transforming Growth Factor- β in Cancer Therapy, Volume II: Cancer Treatment and Therapy, edited by Sonia Jakowlew, 2008

Transforming Growth Factor- β in Cancer Therapy, Volume I: Basic and Clinical Biology, edited by Sonia Jakowlew, 2008

Antiangiogenic Agents in Cancer Therapy, Second Edition, edited by Beverly A. Teicher and Lee M. Ellis, 2007

Apoptosis and Senescence in Cancer Chemotherapy and Radiotherapy, Second Edition, edited by David A. Gerwitz, Shawn Edan Holtz, and Steven Grant, 2007

Molecular Targeting in Oncology, edited by Howard L. Kaufman, Scott Wadler, and Karen Antman, 2007

In Vivo Imaging of Cancer Therapy, edited by Anthony F. Shields and Patricia Price, 2007

Cytokines in the Genesis and Treatment of Cancer, edited by Michael A. Caligiuri, Michael T. Lotze, and Frances R. Balkwill, 2007

Regional Cancer Therapy, edited by Peter M. Schlag and Ulrike Stein, 2007

Gene Therapy for Cancer, edited by Kelly K. Hunt, Stephan A. Vorburger, and Stephen G. Swisher, 2007

Deoxynucleoside Analogs in Cancer Therapy, edited by Godefridus J. Peters, 2006

Cancer Drug Resistance, edited by Beverly A. Teicher, 2006

Histone Deacetylases: Transcriptional Regulation and Other Cellular Functions, edited by Eric Verdin, 2006

Immunotherapy of Cancer, edited by Mary L. Disis, 2006

Biomarkers in Breast Cancer: Molecular Diagnostics for Predicting and Monitoring Therapeutic Effect, edited by Giampietro Gasparini and Daniel F. Hayes, 2006

Protein Tyrosine Kinases: From Inhibitors to Useful Drugs, edited by Doriana Fabbro and Frank McCormick, 2005

Bone Metastasis: Experimental and Clinical Therapeutics, edited by Gurmit Singh and Shafaat A. Rabbani, 2005

The Oncogenomics Handbook, edited by William J. LaRochelle and Richard A. Shimkets, 2005

Camptothecins in Cancer Therapy, edited by Thomas G. Burke and Val R. Adams, 2005

Combination Cancer Therapy: Modulators and Potentiators, edited by Gary K. Schwartz, 2005

Cancer Chemoprevention, Volume 2: Strategies for Cancer Chemoprevention, edited by Gary J. Kelloff, Ernest T. Hawk, and Caroline C. Sigman, 2005

Death Receptors in Cancer Therapy, edited by Wafik S. El-Deiry, 2005

Cancer Chemoprevention, Volume 1: Promising Cancer Chemopreventive Agents, edited by Gary J. Kelloff, Ernest T. Hawk, and Caroline C. Sigman, 2004

Proteasome Inhibitors in Cancer Therapy, edited by Julian Adams, 2004

Nucleic Acid Therapeutics in Cancer, edited by Alan M. Gewirtz, 2004

THE ROLE OF MICROTUBULES IN CELL BIOLOGY, NEUROBIOLOGY, AND ONCOLOGY

Edited by

TITO FOJO, MD, PhD

*Medical Oncology Branch, Center for Cancer Research,
National Cancer Institute, Bethesda, MD*

Editor

Tito Fojo, MD, PhD
Medical Oncology Branch
Center for Cancer Research
National Cancer Institute
Bethesda, MD

Series Editor

Beverly A. Teicher, PhD
Department of Oncology Research
Genzyme Corporation
Framingham, MA

ISBN: 978-1-58829-294-0

e-ISBN: 978-1-59745-336-3

Library of Congress Control Number: 2008920860

© 2008 Humana Press, a part of Springer Science+Business Media, LLC

All rights reserved. This work may not be translated or copied in whole or in part without the written permission of the publisher (Humana Press, 999 Riverview Drive, Suite 208, Totowa, NJ 07512 USA), except for brief excerpts in connection with reviews or scholarly analysis. Use in connection with any form of information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed is forbidden.

The use in this publication of trade names, trademarks, service marks, and similar terms, even if they are not identified as such, is not to be taken as an expression of opinion as to whether or not they are subject to proprietary rights.

While the advice and information in this book are believed to be true and accurate at the date of going to press, neither the authors nor the editors nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.

Cover Illustration: Figure 2B, Chapter 4, "Microtubule-Associated Proteins and Microtubule-Interacting Proteins: Regulators of Microtubule Dynamics," by Maria Kavallaris, Sima Don, and Nicole M. Verrills.

Printed on acid-free paper

9 8 7 6 5 4 3 2 1

springer.com



This book is dedicated to the memory of Dr. George A. Orr, a dear friend and colleague. George was a talented and creative scientist who set very high standards for himself and expected the same from his collaborators. He loved to share concepts and ideas, and many of us had the privilege of interacting and collaborating with him. He inspired and encouraged many young scientists and stimulated them to do their best work. About his own accomplishments, he was extremely humble.

George did his undergraduate and PhD studies at Queen's University, Belfast, N. Ireland. His postdoctoral work was done with Dr. Jeremy Knowles at the University of Oxford and then at Harvard University. George came to the Albert Einstein College of Medicine as an assistant professor in the Department of Molecular Pharmacology in 1978 and rose through the ranks to become a full professor in 1989.

George had many scientific interests but he was particularly dedicated to the development and application of new technologies to enhance our insights into the mode of action of drugs. His participation in the field of microtubule pharmacology and proteomics has opened new avenues of research to all of us. He is sorely missed.

PREFACE

I want to thank all who contributed to this first edition for their hard work and professionalism, and especially for their patience. I hope the readers will find this volume as helpful as I have found it.

There is no doubt that the family of proteins we call the tubulins and the microtubules that they form when they aggregate are extremely important in the cell and, as we are increasingly learning, important in diseases that afflict so many. This field of investigation is a testament to how important both basic and clinical sciences are in understanding disease mechanisms and making inroads into therapies. Without the basic science knowledge that has been accumulated, to which the authors of this work have contributed greatly, we would not be in the position we find ourselves of increasingly understanding disease and advancing therapies. As I read the chapters, I was humbled to think of the insights that so many have contributed to this field, and again became aware of how the collaborative effort of so many is needed to understand the complexities of nature. By working together, many have helped to advance this field. Because of their efforts, we find ourselves with the wealth of knowledge contained in this book. This knowledge gives us so much insight even as it challenges us to continue working. Thanks again to all of the wonderful collaborators for their excellence and their patience.

Tito Fojo, MD, PhD

CONTENTS

Preface	vii
Contributors	xi
List of Color Plates	xiii

1. An Overview of Compounds That Interact with Tubulin and Their Effects on Microtubule Assembly	1
<i>Ernest Hamel</i>	
2. Molecular Mechanisms of Microtubule Acting Cancer Drugs	21
<i>John J. Correia and Sharon Lobert</i>	
3. Microtubule Dynamics: <i>Mechanisms and Regulation by Microtubule-Associated Proteins and Drugs In Vitro and in Cells</i>	47
<i>Mary Ann Jordan and Leslie Wilson</i>	
4. Microtubule Associated Proteins and Microtubule-Interacting Proteins: <i>Regulators of Microtubule Dynamics</i>	83
<i>Maria Kavallaris, Sima Don, and Nicole M. Verrills</i>	
5. The Post-Translational Modifications of Tubulin	105
<i>Richard F. Ludueña and Asok Banerjee</i>	
6. The Isotypes of Tubulin: <i>Distribution and Functional Significance</i>	123
<i>Richard F. Ludueña and Asok Banerjee</i>	
7. The Tubulin Superfamily	177
<i>Richard F. Ludueña and Asok Banerjee</i>	
8. Tubulin Proteomics in Cancer	193
<i>Pascal Verdier-Pinard, Fang Wang, Ruth Hogue Angeletti, Susan Band Horwitz, and George A. Orr</i>	
9. Tubulin and Microtubule Structures	211
<i>Eva Nogales and Kenneth H. Downing</i>	
10. Destabilizing Agents: <i>Peptides and Depsipeptides</i>	227
<i>Lee M. Greenberger and Frank Loganzo</i>	
11. Molecular Features of the Interaction of Colchicine and Related Structures with Tubulin.....	259
<i>Susan L. Bane</i>	

12.	Antimicrotubule Agents That Bind Covalently to Tubulin	281
	<i>Dan L. Sackett</i>	
13.	Microtubule Stabilizing Agents.....	307
	<i>Susan Band Horwitz and Tito Fojo</i>	
14.	Mechanisms of Resistance to Drugs That Interfere with Microtubule Assembly	337
	<i>Fernando Cabral</i>	
15.	Resistance to Microtubule-Targeting Drugs	357
	<i>Paraskevi Giannakakou and James P. Snyder</i>	
16.	Microtubule Stabilizing Agents in Clinical Oncology: <i>The Taxanes</i>	395
	<i>Chris H. Takimoto and Muralidhar Beeram</i>	
17.	Investigational Anticancer Agents Targeting the Microtubule	421
	<i>Lyudmila A. Vereshchagina, Orit Scharf, and A. Dimitrios Colevas</i>	
18.	Microtubule Damaging Agents and Apoptosis	479
	<i>Manon Carré and Diane Braguer</i>	
19.	Microtubule Targeting Agents and the Tumor Vasculature.....	519
	<i>Raffaella Giavazzi, Katiusia Bonezzi, and Giulia Taraboletti</i>	
20.	Neurodegenerative Diseases: <i>Tau Proteins in Neurodegenerative Diseases Other Than AD</i>	531
	<i>André Delacourte, Nicolas Sergeant, and Luc Buée</i>	
21.	Structure, Function, and Regulation of the Microtubule Associated Protein Tau	559
	<i>Janis Bunker and Stuart C. Feinstein</i>	
	Index	577

CONTRIBUTORS

- SUSAN L. BANE, PhD • *Department of Chemistry, State University of New York at Binghamton, Binghamton, NY*
- ASOK BANERJEE, PhD • *Department of Biochemistry, University of Texas Health Science Center, San Antonio, TX*
- MURALIDHAR BEERAM, MD • *Division of Hematology Medical Oncology, Department of Medicine, University of Texas Health Science Center, San Antonio, TX*
- KATIUSCIA BONEZZI, PhD • *Laboratory of Biology and Treatment of Metastasis, Department of Oncology, Mario Negri Institute for Pharmacological Research, Milan, Italy*
- DIANE BRAGUER, PhD • *Formation de Recherche en Evolution-Centre National de la Recherche Scientifique 2737, Faculté de Pharmacie, Université de la Méditerranée, Marseille, France*
- LUC BUÉE, PhD • *INSERM U815, Lille Cedex, France*
- JANIS BUNKER • *Department of Neurology, University of California, San Francisco, CA*
- FERNANDO CABRAL, PhD • *Department of Integrative Biology and Pharmacology, University of Texas-Houston Medical School, Houston, TX*
- MANON CARRÉ • *UMR-Centre National de la Recherche Scientifique 2737, Faculté de Pharmacie, Université de la Méditerranée, Marseille, France*
- A. DIMITRIOS COLEVAS, MD • *Stanford University School of Medicine, Stanford, CA*
- JOHN J. CORREIA, PhD • *Department of Biochemistry, University of Mississippi Medical Center, Jackson, MS*
- ANDRÉ DELACOURTE, PhD • *INSERM Research Center 815, INSERM U422, Lille Cedex, France*
- SIMA DON • *Children's Cancer Institute Australia for Medical Research, Randwick, New South Wales, Australia*
- KENNETH H. DOWNING, PhD • *Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA*
- STUART C. FEINSTEIN, PhD • *Neuroscience Research Institute and Department of Molecular, Cellular and Developmental Biology, University of California, Santa Barbara, CA*
- TITO FOJO, MD, PhD • *Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD*
- PARASKEVI GIANNAKAKOU, PhD • *Department of Medicine, Division of Hematology and Oncology, Weill Medical College of Cornell University, New York, NY*
- RAFFAELLA GIAVAZZI, PhD • *Laboratory of Biology and Treatment of Metastasis, Department of Oncology, Mario Negri Institute for Pharmacological Research, Milan, Italy*
- LEE M. GREENBERGER, PhD • *Enzon Pharmaceuticals, Inc., Piscataway, NJ*
- ERNEST HAMEL, MD • *Toxicology and Pharmacology Branch, Developmental Therapeutics Program, National Cancer Institute at Frederick, National Institutes of Health, NCI-Frederick, Frederick, MD*

- RUTH HOGUE ANGELETTI, PhD • *Laboratory for Macromolecular Analysis and Proteomics, Albert Einstein College of Medicine, Bronx, NY*
- SUSAN BAND HORWITZ, PhD • *Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, NY*
- MARY ANN JORDAN, PhD • *Department of Molecular, Cellular, and Developmental Biology, University of California, Santa Barbara, Santa Barbara, CA*
- MARIA KAVALLARIS, PhD • *Pharmacoproteomics Program, Children's Cancer Institute Australia for Medical Research, Randwick, New South Wales, Australia*
- SHARON LOBERT, RN, MSN, PhD • *Department of Biochemistry and School of Nursing, University of Mississippi Medical Center, Jackson, MS*
- FRANK LOGANZO, PhD • *Wyeth Pharmaceuticals, Oncology Research, Pearl River, NY*
- RICHARD F. LUDUEÑA, PhD • *Department of Biochemistry, University of Texas Health Science Center, San Antonio, TX*
- EVA NOGALES, PhD • *Howard Hughes Medical Institute, Molecular and Cell Biology Department, University of California, Berkeley, CA; and Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA*
- GEORGE A. ORR, PhD (deceased) • *Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, NY*
- DAN L. SACKETT, PhD • *Laboratory of Integrative and Medical Biophysics, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD*
- ORIT SCHARF, PhD • *PSI International, Inc., Fairfax, VA*
- NICOLAS SERGEANT, PhD • *INSERM U422, Lille Cedex, France*
- JAMES P. SNYDER, PhD • *Department of Chemistry, Emory University, Atlanta, GA*
- CHRIS H. TAKIMOTO, MD, PhD, FACP • *South Texas Accelerated Research Therapeutics (START), San Antonio, TX*
- GIULIA TARABOLETTI, PhD • *Laboratory of Biology and Treatment of Metastasis, Department of Oncology, Mario Negri Institute for Pharmacological Research, Milan, Italy*
- PASCAL VERDIER-PINARD, PhD • *Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, NY*
- LYUDMILA A. VERESHCHAGINA, PhD • *PSI International, Inc., Fairfax, VA*
- NICOLE M. VERRILLS, PhD • *School of Biomedical Sciences, University of Newcastle, Callaghan, New South Wales, Australia*
- FANG WANG, PhD • *Laboratory for Macromolecular Analysis and Proteomics, Albert Einstein College of Medicine, Bronx, NY*
- LESLIE WILSON, PhD • *Department of Molecular, Cellular, and Developmental Biology, University of California, Santa Barbara, Santa Barbara, CA*

LIST OF COLOR PLATES

The images listed below appear in the color insert that follows page 478.

- Color Plate 1.** *Fig. 3 Chapter 2:* A ribbon diagram representation of ISA0.pdb, the structure of stathmin–colchicines-tubulin, was rendered with VMD. (See complete caption on p. 26.)
- Color Plate 2.** *Fig. 6 Chapter 2:* Log IC₅₀ vs log K for two classes of antimitotic drugs. (See complete caption on p. 35.)
- Color Plate 3.** *Fig. 7 Chapter 2:* A ribbon diagram representation of 1JFF.pdb, the structure of tubulin derived from Zn-induced sheets, where the mutations that cause stabilization in cold adapted fish are highlighted in red, was rendered with VMD. (See complete caption on p. 40.)
- Color Plate 4.** *Fig. 1 Chapter 3:* Polymerization of microtubules. (See complete caption on p. 48.)
- Color Plate 5.** *Fig. 2 Chapter 3:* Microtubules undergo dynamic instability and tread-milling. (See complete caption on p. 50.)
- Color Plate 6.** *Fig. 3 Chapter 3:* Dynamic instability and the GTP cap. (See complete caption on p. 55.)
- Color Plate 7.** *Fig. 4 Chapter 3:* Antimitotic drugs bind to microtubules at diverse sites that can mimic the binding of endogenous regulators. (See complete caption on p. 58.)
- Color Plate 8.** *Fig. 5 Chapter 3:* Microtubules in two human osteosarcoma cells in interphase of the cell cycle. (See complete caption on p. 63.)
- Color Plate 9.** *Fig. 7 Chapter 3:* Caged fluorescence. (See complete caption on p. 65.)
- Color Plate 10.** *Fig. 8 Chapter 3:* Speckle microscopy. (See complete caption on p. 66.)
- Color Plate 11.** *Fig. 10 Chapter 3:* Organization of the mitotic spindle in human osteosarcoma cells throughout mitosis and in the presence of antimitotic drugs. (See complete caption on p. 70.)
- Color Plate 12.** *Fig. 1 Chapter 4:* Schematic diagram of the major MAPs. (See complete caption on p. 85.)

- Color Plate 13.** *Fig. 2 Chapter 4: MAP binding to microtubules. (See complete caption on p. 85.)*
- Color Plate 14.** *Fig. 3 Chapter 4: Schematic model of interactions of MAPs with microtubules. (See complete caption on p. 86.)*
- Color Plate 15.** *Fig. 4 Chapter 4: Schematic diagram of the stathmin-family of proteins. (See complete caption on p. 95.)*
- Color Plate 16.** *Fig. 5 Chapter 4: Structure of tubulin-colchicine: RB3-tubulin complex. (See complete caption on p. 96.)*
- Color Plate 17.** *Fig. 1 Chapter 8: Model of the tubulin α/β -heterodimer. (See complete caption on p. 196.)*
- Color Plate 18.** *Fig. 1 Chapter 9: Ribbon diagram of the tubulin dimer structure. (See complete caption on p. 213.)*
- Color Plate 19.** *Fig. 2 Chapter 9: Secondary structure for α - and β -tubulin indicated on the pig sequences. (See complete caption on p. 215.)*
- Color Plate 20.** *Fig. 3 Chapter 9: Topological structures around the nonexchangeable nucleotide site. (See complete caption on p. 215.)*
- Color Plate 21.** *Fig. 4 Chapter 9: Protofilament and interface structures. (See complete caption on p. 216.)*
- Color Plate 22.** *Fig. 5 Chapter 9: Cross-section of the three-dimensional microtubule density map. (See complete caption on p. 218.)*
- Color Plate 23.** *Fig. 6 Chapter 9: Surface view of the microtubule density map, seen from the outside with the plus end up. (See complete caption on p. 219.)*
- Color Plate 24.** *Fig. 7 Chapter 9: Protofilament arrangements and contacts in (A) microtubules, (B) the Zn-sheets. (See complete caption on p. 220.)*
- Color Plate 25.** *Fig. 8 Chapter 9: The Taxol-binding site. (See complete caption on p. 221.)*
- Color Plate 26.** *Fig. 9 Chapter 9: Superposition of Taxol (yellow) and epothilone-A (blue) in the conformations and orientations in which they bind tubulin. (See complete caption on p. 222.)*
- Color Plate 27.** *Fig. 10 Chapter 9: Detail of the interface between protofilaments, as seen from the inside of the microtubule. (See complete caption on p. 223.)*

- Color Plate 28.** *Fig. 4 Chapter 10:* Model of the HTI-286 and vinblastine photolabeling domains in tubulin. (See complete caption on p. 242.)
- Color Plate 29.** *Fig. 4 Chapter 11:* Structures of (7*S*,a*R*)-(-)-colchicine (left) and (7*R*,a*S*)-(+)-colchicine (right), illustrating the atropisomers of the colchicine ring system. (See complete caption on p. 268.)
- Color Plate 30.** *Fig. 6 Chapter 11:* Isocolchicine vs colchicine. (See complete caption on p. 269.)
- Color Plate 31.** *Fig. 8 Chapter 11:* Stereoview of one of the tubulin-colchicine complexes from the crystal structure of tubulin/colchicine:stathmin-like domain complex (PDB 1SA0). (See complete caption on p. 272.)
- Color Plate 32.** *Fig. 9 Chapter 11:* Stereoview of the colchicine-binding site of tubulin/colchicine:stathmin-like domain complex (PDB 1SA0). (See complete caption on p. 273.)
- Color Plate 33.** *Fig. 1 Chapter 12:* The position and exposure of cysteine 239 in β -tubulin (β cys239). (See complete caption on p. 286.)
- Color Plate 34.** *Fig. 3 Chapter 13:* Paclitaxel-induced tubulin polymerization *in vitro*. (See complete caption on p. 311.)
- Color Plate 35.** *Fig. 4 Chapter 13:* Paclitaxel-induced mitotic arrest with aster formation *in vivo*. (See complete caption on p. 312.)
- Color Plate 36.** *Fig. 3 Chapter 14:* Structure of an $\alpha\beta$ -tubulin heterodimer. (See complete caption on p. 347.)
- Color Plate 37.** *Fig. 1 Chapter 15:* An overview of some of the ligand-binding sites on the $\alpha\beta$ -tubulin dimer. (See complete caption on p. 359.)
- Color Plate 38.** *Fig. 2 Chapter 15:* Structures of taxane-binding site microtubule stabilizing drugs. (See complete caption on p. 362.)
- Color Plate 39.** *Fig. 3 Chapter 15:* The Asp26, Phe270, Ala364, and Glu198 residues are mutated following drug selection with TaxolTM. (See complete caption on p. 367.)
- Color Plate 40.** *Fig. 4 Chapter 15:* The Ala364 cluster representing the β Ala364Thr mutation seen in the ovarian carcinoma 1A9 cells. (See complete caption on p. 368.)
- Color Plate 41.** *Fig. 5 Chapter 15:* Binding models of TaxolTM and taxotere in the taxane-binding pocket of the β Asp26Glu mutant seen in the epidermoid carcinoma KB-31 cells. (See complete caption on p. 369.)

- Color Plate 42.** *Fig. 6 Chapter 15:* Representation of the locus of the β Glu198Gly mutation induced by TaxolTM-selection in the MDA-MB-231 breast cancer cells. (See complete caption on p. 369.)
- Color Plate 43.** *Fig. 7 Chapter 15:* The $\alpha\beta$ -tubulin dimer illustrating the spatial relationships of GDP, GTP, TaxolTM, and α Ser379 in the context of the TaxolTM-induced α Ser379Arg mutation in the A549 lung cancer cells. (See complete caption on p. 370.)
- Color Plate 44.** *Fig. 8 Chapter 15:* The α Ser379Arg mutation is located on strand B10 in α -tubulin. (See complete caption on p. 371.)
- Color Plate 45.** *Fig. 9 Chapter 15:* Environment around the C-3 to C-7 oxygen substituents of EpoA bound to β -tubulin. (See complete caption on p. 372.)
- Color Plate 46.** *Fig. 10 Chapter 15:* At lower left, Ala231 (magenta) surrounded by a hydrophobic pocket (green) is subjected to the Ala231Thr mutation, which presumably perturbs the His227 interaction with dEpoB (represented by EpoA at their binding pocket). (See complete caption on p. 374.)
- Color Plate 47.** *Fig. 11 Chapter 15:* TaxolTM and EpoA tubulin-bound structures overlap as determined by the corresponding electron crystallographic structures. (See complete caption on p. 376.)
- Color Plate 48.** *Fig. 12 Chapter 15:* Fluorescence *in situ* hybridization analysis of 1A9 cells Depicts tubulin LOH in the drug-resistant 1A9-A8 cells. (See complete caption on p. 379.)
- Color Plate 49.** *Fig. 13 Chapter 15:* Schematic representation of Evolution of Microtubule-Targeting Drug-Induced Resistance. (See complete caption on p. 379.)
- Color Plate 50.** *Fig. 15 Chapter 15:* Structures of Vinca-binding site microtubule-destabilizing drugs. (See complete caption on p. 380.)
- Color Plate 51.** *Fig. 16 Chapter 15:* The colchicine and podophyllotoxin binding sites as determined by X-ray crystallography. (See complete caption on p. 381.)
- Color Plate 52.** *Fig. 17 Chapter 15:* Photoaffinity labeled peptides and mutations around the Vinca site. (See complete caption on p. 383.)
- Color Plate 53.** *Fig. 18 Chapter 15:* Closeup of the photoaffinity labeled peptides and mutations around the Vinca site. (See complete caption on p. 384.)

- Color Plate 54.** *Fig. 19 Chapter 15:* The local environments of the β Asn100Ile and β Leu240Ile mutations. (See complete caption on p. 384.)
- Color Plate 55.** *Fig. 20 Chapter 15:* Photoaffinity labeled peptides and mutations around the α -tubulin hemiasterlin-binding site. (See complete caption on p. 386.)
- Color Plate 56.** *Fig. 21 Chapter 15:* Local environments of the α Ala12Ser, β Ser172Ala, and β Arg221His mutations. (See complete caption on p. 387.)
- Color Plate 57.** *Fig. 22 Chapter 15:* A potential interaction train for α Ser165Pro and β Ser172Ala across the $\alpha\beta$ -tubulin dimer interface (dotted line); α Ser165 (magenta), β Ser172 (green). (See complete caption on p. 388.)
- Color Plate 58.** *Fig. 1 Chapter 18:* Cellular morphology of human mitotic and apoptotic cells. (See complete caption on p. 480.)
- Color Plate 59.** *Fig. 2 Chapter 18:* Two main pathways to apoptosis. (See complete caption on p. 483.)
- Color Plate 60.** *Fig. 3 Chapter 18:* Linear structure of antiapoptotic Bcl-2, proapoptotic Bax, and proapoptotic Bim. (See complete caption on p. 485.)
- Color Plate 61.** *Fig. 4 Chapter 18:* Potential role of Bcl-2 family proteins in the mitochondrial permeability. (See complete caption on p. 486.)
- Color Plate 62.** *Fig. 5 Chapter 18:* Models for release of mitochondrial intermembrane space factors. (See complete caption on p. 488.)
- Color Plate 63.** *Fig. 6 Chapter 18:* Schematic representations of mammalian IAPs. (See complete caption on p. 490.)
- Color Plate 64.** *Fig. 1 Chapter 19:* Tubulin-targeting agents. (See complete caption on p. 520.)
- Color Plate 65.** *Fig. 2 Chapter 19:* Effects of vascular disrupting agents. (See complete caption on p. 521.)
- Color Plate 66.** *Fig. 1 Chapter 21:* Domain structure of the 6-tau isoforms expressed in the central nervous system. (See complete caption on p. 561.)
- Color Plate 67.** *Fig. 4 Chapter 21:* Three possible pathways of tau-mediated neuronal cell death. (See complete caption on p. 567.)

COMPANION CD-ROM

The CD-ROM that accompanies this book contains all of the images that appear in color in the book's insert.